Neuropsychiatric Disorders Treatment Market, By Disorder (Major Depressive Disorder, Bipolar Disorder, Anxiety Disorders, Schizophrenia Spectrum Disorders, Trauma- and Stressor-Related Disorders, Obsessive-Compulsive and Related Disorders, Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Substance Use Disorders, Sleep-Wake Disorders, Neurocognitive Disorders, Movement Disorders with psychiatric symptom control, Eating Disorders, and Personality Disorders), By Drug Class (Antidepressants, Antipsychotics, Mood Stabilizers, Anxiolytics and Sedative-Hypnotics, ADHD Medications, Cognitive Enhancers, Substance Use Disorder Medications, Movement and Impulse Control Agents, and Adjunctive Symptom-Control Agents), By Route of Administration (Oral, Parenteral, Intranasal, Transdermal, and Sublingual or Buccal), By Molecule Type (Small molecules, Biologics, and Combination drugs (fixed-dose combinations), By Formulation Type (Immediate release, Extended release or controlled release, Long-acting depot formulations, Orally disintegrating formulations, Liquid oral formulations, and Prodrug formulations), By Patient Age Group (Pediatric, Adolescent, and Adult/Geriatric), By Care Setting (Inpatient, Outpatient, Community-based Care, Home-based Care, and Telehealth and Virtual Care), By Provider Type (Psychiatrists, Neurologists, Primary Care Physicians, Psychologists and Therapists, Addiction Medicine Specialists, and Integrated Care Teams), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Payment Type (Public and Private), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2025-2032)